

IBS: Pathophysiology and Management Challenges

Muhammad Akram¹, Isaac John Umaru², Abid Mahmood³, Mohammed Khudhair Hasan⁴, Hind A. Abdulghafoor⁵, Fahad Said Khan⁶, Fethi Ahmet Ozdemir⁷, Gaweł Sołowski⁸, Jaouher Ben Ali⁹, Jehan Mohammed Al-Musawi¹⁰

^{1,3}Government College University Faisalabad, Pakistan; ²Federal University Wukari, Taraba State, Nigeria; ⁴Al Manara College for Medical Sciences, Maysan, Iraq; ⁵University of Fallujah, Iraq; ⁶University of Poonch Rawalakot, Azad Jammu and Kashmir, Pakistan;

^{7,8}Bingol University, Bingol, Türkiye; ⁹University of Tunis, Tunisia;

¹⁰University of Kufa, Najaf, Iraq

makram_0451@yahoo.com

Article Info:

Submitted:	Revised:	Accepted:	Published:
Apr 5, 2025	Apr 20, 2025	May 2, 2025	May 7, 2025

Abstract

Irritable Bowel Syndrome (IBS) is a widespread functional gastrointestinal ailment with chronic abdominal pain, change in bowel movements, and reduced quality of life as hallmarks. Unlike organic diseases, IBS is idiopathic—diagnosed in the absence of structural or biochemical disturbances, which makes disease management more difficult. The causes of IBS are heterogeneous: dysregulation of gut-brain axis, visceral hypersensitivity, motility disorders, changes in microbiome, and psychosocial aspects contribute to it. This article explains causes of IBS, symptomatology, diagnostic criteria, and treatment options multidisciplinary with a focus on tailored dietary intervention, medication, psychotherapy, as well as alternative methods.

Keywords: Irritable bowel syndrome, a type of functional gastrointestinal disorder, chronic cramps, gut-brain interaction, Rome IV criteria, low FODMAP diet, nervous system sensitivity, intestinal tract hypomotility subtype of IBS, intestinal tract hypermotility subtype of IBS

Introduction

IBS is one of the most prevalent gastrointestinal disorders having an estimated world prevalence of 10–15% (Black et al 2020). Although IBS has become a commonplace diagnosis in modern times, it is still not well understood, insufficiently diagnosed, and undertreated. Differentiating it from inflammatory or structural diseases like Crohn's disease and peptic ulcers, IBS is categorized as a functional disorder because there is no detectable organic pathology, rather the gastrointestinal systems functions abnormally. Most commonly it is defined by the recurrent abdominal pain that occurs along with alterations in bowel movements: either constipation, IBS-C, or diarrhea, known as IBS-D, or both, classified as mixed, IBS-M. All IBS subtypes are enduring and multifaceted, which makes life difficult not only for patients but also for doctors concerned.

Etiology and Pathophysiology

As of today, the main cause for this condition still remains unknown. However, many researchers attribute IBS to one or more reasons (Whitehead et al 2002). It could likely stem from the relationship of the intestines with the nervous system. Moreover, visceral hypersensitivity, as well as disordered bowel movements (“motility”) which alters the pause and go nature of gut action, contributes to IBS. This condition might stem from a change in gut bacteria — the microorganisms residing in the intestines — especially after gastrological illnesses or the use of antibiotics (post-infectious IBS). Psychological factors like stress, depression, anxiety or a combination of all escalate the matter and correlate to symptom severity. Furthermore, some patients suffer from immune dysregulation with is under active immune systems and low-grade inflammation within the intestines that surrounds the digestive part. Family traits, coupled with physical and emotional trauma in early childhood, might also shape the development of this condition (Lieberman et al 2007).

Clinical Presentation and Subtypes

While there are multiple ways in which IBS can manifest, the hallmark characteristic of all forms is recurrent abdominal discomfort in relation to bowel movements and the alteration in geometric form, frequency, or consistency of stools. The diagnostic criteria of Rome IV,

which is the latest set of criteria defining symptoms and utilized for diagnosis as of now, states that symptoms must have been present at least once a week for the last three months (Simren et al 2017). Furthermore, IBS can also be divided into subtypes based on predominant psychopathology into four categories: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed (IBS-M), and unclassified (IBS-U). Patients may provide additional information such as bloating, the presence of excess gas, urgency, the feeling of incomplete evacuation, and the presence of mucus in stools. Contrary to inflammatory diseases, IBS fails to cause fever, rectal hemorrhage, or clinically important weight loss—so called red flag symptoms that clearly justify further examination. The waxing and waning characteristic of symptoms, which are often cyclic in nature, can be very distressful and undermining participants' health-related quality of life, which means that IBS should not only be considered as a disorder of the intestine, but rather a biopsychosocial one (Jacobs et al 2007).

Diagnosis

IBS is a diagnosis that can be made only after all other possibilities have been considered, which means it is an exclusion diagnosis. Additionally, the medical history and physical examination should be done in detail, focusing on the symptom's patterns, duration, and potential red flags (Talley et al 2010). Celiac disease, inflammatory bowel disease, infections, or malignancy are often ruled out through routine blood work, stool tests, and imaging of the abdomen. The Rome IV diagnostic criteria, which is a symptom-based approach that IBS positiers rely on most, still remains the gold standard and has minimal emphasis on additional testing. Some instances do call for a colonoscopy, particularly for patients older than 50 or those showing concerning signs such as rectal bleeding alongside anemia or a family history of colon cancer. Patients often seek multiple consultations because of anxiety surrounding their symptoms, so it's safe to assert that IBS diagnosis requires confident estimation. Reassuring and better explaining a patient's condition using functional aspects of IBS, along with a solid compassionate outline of diagnosis, enhances treatment compliance.

Treatment and Management

Integrative and personalized strategies are needed to manage IBS owing to its multifaceted etiology (Nelkowska et al 2019). Educating the patient, providing reassurance, and modifying lifestyle are common initial approaches. Managing diet is extremely important, and restricting symptom-inducing carbohydrate foods (the low FODMAP diet) is effective for many patients. Soluble fiber may aid to some extent with IBS-C, while anti-diarrheal agents such as loperamide are effective in IBS-D. Other medications for pain include antispasmodics (hyoscine, dicyclomine); also, lowiberin and some laxatives or secretagogues (linaclotide), as well as some serotonergic agents (alosetron), are prescribed for constipation and diarrhea, respectively. Changing the gut-brain axis, TCAs, and sometimes even SSRIs, however in low doses, are employed to decrease pain perception and inflammation (Stanculete et al 2021). Probiotics, along with gut-focused psychotherapies like CBT and gut-directed hypnotherapy, have also proved useful clinically. In a few cases, a gastroenterologist or behavioral therapist needs to be consulted.

Prevention and Long-Term Management

Despite IBS being a long-lasting ailment, with effective long-term care, life can be easier and symptom control is possible. Careful management of stress, regular workouts, and consistency in dietary habits all fall under preventive strategies (Sharkey et al 2013). Alongside these, dietary avoidance of specific triggers, proper hydration, good sleeping habits, and proper sleep have great effects on reducing flare-ups. For better self-awareness, patients should be motivated to actively track their symptoms and identify changes in their lifestyle. Directly entails honesty, trust, and strong relationship between the patient and the clinician, meaning fosters collaborative management of the condition for better results. It is best practice to routinely follow up patients with set intervals to evaluate the effectiveness of the treatment, look for new symptoms, and change the required intervention or subset of interventions if necessary (van et al 1999). While it is accepted that IBS does not increase the risk of mortality or cancer, the need for care that is sympathetic but with a more refined lens focused on the psychological aspects highlights a shift in approach to care needed.

Conclusion

Irritable Bowel Syndrome (IBS) is a complex and often debilitating illness that continues to challenge patients and clinicians because of its functional nature. Its precise cause is yet to be determined but the pathology surrounding the gut-brain axis, microbiota, and psychosocial factors seeks to understand and provide possible treatment. Effective IBS management requires a comprehensive approach that considers each patient's specific symptoms, triggers, and psychosocial factors. To be readily achieved, dietary therapy, pharmacologic agents, psychological support, and patient education need to be synergized. Based on compassion, most patients are able to attain considerable symptom relief and improve their quality of life, highlighting that with the right evidence-based approaches, IBS does not need to be a lifelong burden.

Reference

- Black, C. J., & Ford, A. C. (2020). Global burden of irritable bowel syndrome: Trends, predictions and risk factors. *Nature Reviews Gastroenterology & Hepatology*, 17(8), 473-486. <https://doi.org/10.1038/s41575-020-0290-4>
- Jacobs, C. S. (2007). The common sense model, quality of life and symptom frequency in irritable bowel syndrome (IBS). University of Surrey.
- Lieberman, A. F., & Knorr, K. (2007). The impact of trauma: A developmental framework for infancy and early childhood. *Pediatric Annals*, 36(4), 209-215. <https://doi.org/10.3928/0090-4481-20070401-08>
- Nelkowska, D. D. (2019). Treating irritable bowel syndrome through an interdisciplinary approach. *Annals of Gastroenterology*, 33(1), 1. <https://doi.org/10.20524/aog.2019.0410>
- Sharkey, B. J., & Gaskill, S. E. (2013). Fitness & health. *Human Kinetics*.
- Simren, M., Palsson, O. S., & Whitehead, W. E. (2017). Update on Rome IV criteria for colorectal disorders: Implications for clinical practice. *Current Gastroenterology Reports*, 19, 1-8. <https://doi.org/10.1007/s11894-017-0556-9>
- Stanculete, M. F., Dumitrascu, D. L., & Drossman, D. (2021). Neuromodulators in the brain-gut axis: Their role in the therapy of the irritable bowel syndrome. *Journal of Gastrointestinal and Liver Diseases*, 30(4), 517-525. <https://doi.org/10.15403/jgld-3391>
- van Weel, C., & Knottnerus, J. A. (1999). Evidence-based interventions and comprehensive treatment. *The Lancet*, 353(9156), 916-918. [https://doi.org/10.1016/S0140-6736\(99\)03345-4](https://doi.org/10.1016/S0140-6736(99)03345-4)

Muhammad Akram, Isaac John Umaru, Abid Mahmood, Mohammed Khudhair Hasan, Hind A. Abdulghafoor, Fahad Said Khan, Fethi Ahmet Ozdemir, Gawel Solowski, Jaouher Ben Ali, Jehan Mohammed Al-Musawi

Whitehead, W. E., Palsson, O., & Jones, K. R. (2002). Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? *Gastroenterology*, 122(4), 1140-1156.
<https://doi.org/10.1056/NEJMra000047>